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REVIEW
Abstract: COPD is a progressive illness with worldwide impact. Patients invariably reach a 
point at which they require palliative interventions. Dyspnea is the most distressing symptom 
experienced by these patients; when not relieved by traditional COPD management strategies it 
is termed “refractory dyspnea” and palliative approaches are required. The focus of care shifts 
from prolonging survival to reducing symptoms, increasing function, and improving quality 
of life. Numerous pharmacological and non-pharmacological interventions can achieve these 
goals, though evidence supporting their use is variable. This review provides a summary of 
the options for the management of refractory dyspnea in COPD, outlining currently available 
evidence and highlighting areas for further investigation. Topics include oxygen, opioids, 
psychotropic drugs, inhaled furosemide, Heliox, rehabilitation, nutrition, psychosocial support, 
breathing techniques, and breathlessness clinics.
Keywords: chronic obstructive pulmonary disease (MeSH), dyspnea (MeSH), palliative care 
(MeSH), analgesics, opioid (MeSH), oxygen (MeSH)
Introduction
COPD is an international health problem with a worldwide prevalence of at least 
9.34/1000 in men and 7.33/1000 in women (1990 estimate) (Murray and Lopez 1996a, 
1996b). It is the fourth leading cause of death worldwide (WHO 2000). The burden of 
COPD is expected to increase, such that by 2020, it will be the ﬁ  fth leading cause of 
lost disability-adjusted life years worldwide (Murray and Lopez 1996a, 1996b).
The 2001 Global Strategy for the Diagnosis, Management, and Prevention of COPD 
(GOLD) guidelines recommend a step-wise approach to care as lung function declines 
and patients become more symptomatic with the addition of therapeutic interventions 
including bronchodilators (short- and long-acting), anti-cholinergic agents, pulmonary 
rehabilitation, inhaled glucocorticoids, and oxygen (Pauwels et al 2001). While this 
strategy has improved management, the only intervention that slows progression of 
disease is smoking cessation, as has been documented in the Lung Health Study I, 
EUROSCOP, the Copenhagen City Lung Study, and the ISOLDE trial (Burrows 
et al 1987; Pauwels et al 1999). Additionally, while oxygen improves survival in 
hypoxemic patients with COPD, survival is no different from similar patients with 
no hypoxemia (Murray and Nadel 2000). As a result, COPD remains a progressive, 
incurable illness.
Predicting survival and timing of disability in COPD is difﬁ  cult. Lung function 
decreases with age and age is inversely proportional to survival. Decline in lung 
function is not always continuous. The course of COPD is punctuated by acute 
exacerbations with deterioration in lung function that is less likely to completely 
resolve as disease progresses (Burrows 1990). Exacerbations increase in frequency 
as lung function declines and some individuals experience a more rapid deterioration 
than others. These “rapid decliners” have been identiﬁ  ed in prospective studies but it 
is not clear what sets them apart (Gottlieb et al 1996). Other variables that inﬂ  uence 
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mortality include forced expiratory volume in one second 
(FEV1), nutritional status, and associated co-morbid disease 
(Melbostad et al 1997). Mortality increases as FEV1 declines 
(Mannino et al 2003), although mortality is best predicted 
by a multifactorial staging system that includes factors 
in addition to FEV1 (Celli et al 2004). Overall, patients 
with COPD follow a trajectory of illness characterized 
by intermittent worsening followed by improvements in 
performance status with an overall progression towards 
complete disability and then death (Lunney et al 2002, 2003) 
(Figure 1).
As time passes, quality of life (QOL) diminishes, most 
often as a result of increasing dyspnea that eventually 
becomes completely disabling. Conventional methods of 
alleviating dyspnea by modifying the disease begin to fail 
and it becomes more difﬁ  cult to optimize comfort. Care of 
these patients is made all the more difﬁ  cult by the challenge 
in identifying those that are “end-stage” and/or would derive 
beneﬁ  t from palliative interventions.
Need for dyspnea management 
and palliative care
There is increasing interest in identifying COPD patients who 
would beneﬁ  t from palliative interventions and palliative care 
(Skilbeck et al 1998; Gore et al 2000; Edmonds et al 2001). 
The studies are limited by the lack of a clear deﬁ  nition of 
“end-stage” COPD but do uncover important issues. Skilbeck 
et al (1998) looked at 63 patients with COPD who were 
over the age of 55 and had been admitted to the hospital 
with an exacerbation in the preceding 6 months. There 
were high levels of morbidity and signiﬁ  cant functional 
limitations. Ninety-ﬁ  ve percent of patients reported that 
breathlessness was their most significant debilitating 
symptom, with 60% indicating the highest severity level on 
the scale. Other symptoms causing disability included pain, 
fatigue, difﬁ  culty sleeping, and thirst. Decreased physical, 
social, and emotional functioning were also described. The 
authors concluded that COPD patients had a high burden 
of poorly controlled symptoms, most likely as a result of 
a focus on crisis intervention with management of acute 
exacerbations as opposed to continued improvement in 
baseline functioning.
Two subsequent studies looked at the care of “end-stage” 
COPD patients as compared with the care of patients with 
lung cancer. Gore et al (2000) studied 50 patients over 
age 60 with COPD (deﬁ  ned as FEV1 <0.75 L and at least 
one admission for hypercapneic respiratory failure) and 
50 patients over age 60 with inoperable non-small cell lung 
cancer. The study assessed QOL by several measures as 
well as the quantity and quality of medical and social care 
received. All data were obtained by a single interviewer. 
Patients with COPD had consistently lower (ie, worse) 
scores on the MOS Short Form-36 Health Survey (SF-36) 
than patients with lung cancer on all subscales (p≤0.05) with 
the exception of those measuring emotional and physical 
roles. COPD patients also scored higher (ie, worse) than 
lung cancer patients on the both the depression (10.18 [SD 
3.95] vs 7.22 [SD 5.16], p<0.01) and anxiety (11.44 [SD 
4.76] vs 7.20 [SD 5.25], p<0.0001) subscales of the Hospital 
Anxiety and Depression Scale (HADS). Finally, 82% of 
COPD patients were housebound, compared with 36% of 
those with lung cancer. Despite these ﬁ  ndings, none of the 
COPD patients had received or been offered specialist 
palliative care (Gore et al 2000). Some methodological ﬂ  aws 
weaken these results (Hill and Muers 2000). There were 
more females than males in the COPD group; female sex is 
associated with higher levels of symptomatology and lower 
health status (van Wijk and Kolk 1997) as well as higher 
scores on the HADS (Aass et al 1997). Additionally, the 
lung cancer patients were a particularly well group whose 
survival exceeded the typical median survival for such 
patients in the UK (Hill and Muers 2000). Even in light of 
these discrepancies, the data produced by Gore et al (2000) 
support the view that there is a need for better palliative 
Figure 1 The trajectory of illness of COPD follows a progressive course with 
declines in function alternating with periods of improvement. As the disease 
progresses, the focus of care shifts from life-prolonging therapies to palliative 
interventions aimed at reducing symptoms, improving function, and improving 
quality of life. Reprinted from Lunney JR, Lynn J, Hogan C. 2002. Proﬁ  les of 
older medicare decedents. J Am Geriatr Soc, 50:1108–12. Copyright © 2002 with 
permission from Blackwell Publishing Ltd.
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care for patients with COPD. These data are in agreement 
with those of Skilbeck et al (1998) and were further 
supported by a later study published by Edmonds et al 
(2001).
Edmonds et al (2001) looked at the needs of patients 
with chronic lung disease or lung cancer in their ﬁ  nal year 
of life as reported by a surrogate (relative, friend, or car-
egiver). Patients with COPD had troublesome symptoms, 
including pain, cough, anorexia, mouth problems, and 
insomnia. Breathlessness was most common, with 94% 
of respondents reporting this symptom during the ﬁ  nal 
year of life and 76% rating it as “very distressing.” This 
contrasts with the lung cancer patients, 78% of whom 
reported breathlessness (p<0.001) with 60% describing 
it as “very distressing” (p=0.024). COPD patients had 
signiﬁ  cantly more frequent (p<0.001) and severe (p<0.024) 
breathlessness than the lung cancer group. Similar to the 
ﬁ  ndings of Gore et al (2000), patients with lung cancer in 
the Edmonds et al (2001) study were more likely to have 
received hospice care (30%) as compared with those with 
COPD (0%, p<0.001).
Together, these data highlight that the symptoms of 
patients with COPD are at least as severe as those of patients 
with lung cancer and that these patients would beneﬁ  t from 
better symptom management, particularly in the area of 
dyspnea. Despite the degree of symptomatology, COPD 
patients less frequently access palliative care.
Deﬁ  nition and mechanisms of 
dyspnea
Dyspnea is a symptom that is difficult to understand and 
difficult to define, for both physicians and patients. The 
experience of dyspnea is the combination of a sensation 
involving activation of neural pathways and a perception 
on the part of the patient (ATS 1999). Descriptions of 
dyspnea vary widely and depend, at least in part, on a 
patient’s underlying disease, ethnic–racial background, 
previous experiences, and emotional state. In an attempt 
to incorporate each of these ideas, an American Thoracic 
Society consensus panel proposed that dyspnea is “a 
subjective experience of breathing discomfort that 
consists of qualitatively distinct sensations that vary 
in intensity. The experience derives from interactions 
among multiple physiological, psychological, social, 
and environmental factors, and may induce secondary 
physiological and behavioral responses” (ATS 1999 
p 322). 
The pathophysiological mechanisms that govern the 
development of dyspnea are poorly understood. Dyspnea 
seemingly results from a mismatch of respiratory motor 
activity and incoming afferent activity, including 
information from chemo-, vagal, mechano-, pulmonary 
stretch, and muscle receptors (ATS 1999). The interaction 
between these individual components is only starting to 
be understood and there are clearly situations that cannot 
be deﬁ  ned by looking at only these factors. For example, 
increases in PaCO2 plus decreases in PaO2 and/or pH 
detected by peripheral chemoreceptors result in dyspnea. 
However, not all patients with abnormal blood gases 
experience dyspnea and many dyspneic patients have 
normal blood gases (Mountain et al 1978; Stulbarg et al 
1989; Kikuchi et al 1994).
Researchers have tried to deﬁ  ne the key parameters of 
breathlessness. Fifteen years ago, Simon and colleagues tried 
to look at correlates of dyspnea with underlying induced 
pathophysiology in normal volunteers (Simon et al 1989), 
and in disease pathophysiology in people with established 
single causes of dyspnea (Simon et al 1990). There were 
some clusters deﬁ  ned. A decade later, that idea was further 
developed by Harver et al (2000) in their work which deﬁ  ned 
three key domains of breathlessness: depth and frequency of 
breathing, perceived urge of need to breathe, and difﬁ  culty 
breathing and phase of respiration.
Goals of palliative interventions 
for intractable dyspnea: relief of 
breathlessness and improving 
function
Patients often complain of dyspnea that seems out of 
proportion to apparent physical disability or functional 
impairment. It can be difﬁ  cult to care for these patients 
as the usual dictum to treat the dyspnea by treating the 
underlying disease cannot guide therapy. There is also a 
substantial – and growing – population of patients whose 
COPD has been maximally treated but who are still 
breathless. Patients whose dyspnea cannot be alleviated 
through further treatment of their COPD have intractable 
dyspnea or refractory dyspnea (Abernethy et al 2003).
There are palliative options that can improve symptoms 
and QOL for COPD patients with intractable dyspnea 
(Figure 2). The purpose of this review is to outline these 
options, discuss the data behind them, and provide practical 
guidance. Incorporating this information into clinical 
practice ﬁ  rst requires that the goals of therapy are clearly International Journal of COPD 2006:1(3) 292
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articulated. We assume here that extending survival is not 
the primary goal of therapy. Palliative interventions should 
not reduce life expectancy, but can be beneﬁ  cial even when 
they do not extend survival. The therapeutic interventions 
will therefore be examined in terms of their impact on relief 
of the sensation of breathlessness and/or their impact on 
functional status.
Oxygen therapy
Home oxygen therapy is commonly prescribed for patients 
with severe COPD. Two randomized controlled trials, one 
by the Medical Research Council Working Party (MRCWP 
1981) and the other by the Nocturnal Oxygen Therapy Trial 
Group (NOTT) (NOTTG 1980), demonstrated that long-
term oxygen therapy (LTOT) prolongs survival in COPD 
patients with hypoxemia (PaO2 <55 mmHg). LTOT oxygen 
is administered at home for at least 12–15 hours per day. 
In the NOTT trial, supplemental criteria for the use of LTOT 
in moderately hypoxemic patients (PaO2 55–59 mmHg) 
included pulmonary hypertension, cor pulmonale, and 
secondary polycythemia (hematocrit ≥55%). These two 
studies form the basis on which LTOT is funded by third-
party payers for the management of hypoxemic patients 
worldwide. The goal is prolonging survival. The studies do 
not focus on symptomatic treatment of dyspnea, improved 
function in activities of daily living, and QOL outcomes, nor 
do they guide treatment of patients with disabling dyspnea 
who are not hypoxemic.
Palliative oxygen is prescribed when the primary goal 
is relief of breathlessness. In this setting the data are less 
clear. McDonald et al (1995) examined the effects of pallia-
tive oxygen in non-hypoxemic patients with severe COPD. 
The effect of medical air vs oxygen on exercise perform-
ance and QOL was examined in a 12-week, double-blind, 
 Evidence generally supports use of intervention for the management of refractory dyspnea 
in COPD. 
 Current available evidence does not support use of this intervention. 
 Further investigation required. 
Non-pharmacologic Pharmacologic Oxygen
Hypoxemic ↑ Rehabilitation  ↑ Opioids
Non-hypoxemic ↔  Oral ↑  Nutrition ↔
Parenteral ↑  Psychosocial support ↔ 
Inhaled ↓ Breathing techniques ↑ 
Psychotropic drugs Positioning
Anxiolytics ↔ Pursed lip breathing
Phenothiazines ↓ Breathlessness clinics ↔ 
Selective serotonin reuptake inhibitors ↔ 
Inhaled furosemide ↔ 
Heliox ↔ 
Figure 2 Palliative interventions for refractory dyspnea.International Journal of COPD 2006:1(3) 293
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randomized crossover study involving 26 patients with 
severe COPD, mean resting PaO2 69 mmHg (range 
58–82 mmHg), and exertional dyspnea severe enough to 
interfere with daily activities. There were small, statistically 
signiﬁ  cant (p<0.05) increases in 6-minute walk distance 
with oxygen. Both oxygen and medical air improved 
QOL from baseline but did not affect the sensation of 
breathlessness. The authors concluded that there was little 
evidence to support prescription of home oxygen for COPD 
patients with only mild hypoxemia.
Booth et al (2004) systematically reviewed the published 
English-language literature through 2003 regarding the use 
of palliative oxygen for the management of breathlessness in 
cancer, COPD, and heart failure. They focused on studies in 
which breathlessness was measured by intensity scales such 
as the visual analog scale (VAS) or Borg scales. Studies 
involving the use of supplemental oxygen in patients with 
COPD were divided as follows: 1) those investigating the 
use of oxygen at rest; 2) those investigating the use of 
oxygen before, during and after exercise (ie, “short burst” 
oxygen therapy); and 3) those investigating LTOT where 
breathlessness was an outcome in addition to survival. 
A complete list of the studies included is provided at the 
end of this article. 
Most of the studies were small (range 5–50 patients) 
and poorly controlled. The results were inconsistent and 
remarkably patient dependent. The authors concluded that 
oxygen at rest may be one part of a palliative treatment plan 
for the care of patients with COPD, but that it should be used 
only after an “n of 1” assessment as described by Bruera 
et al (1992). The goal of the “n of 1” individualized patient 
trial is to assess the impact of the oxygen in terms of both 
breathlessness and personal QOL. The recommendations 
for “short burst” oxygen were similar, reflecting the 
potential for some patients to beneﬁ  t. For example, one 
study demonstrated great relief of dyspnea with oxygen for 
some participants, although the cumulative results for all 
patients in the trial were not statistically signiﬁ  cant (Booth 
et al 1996). Another study showed that dyspnea before and 
after exertion in patients with COPD could be relieved 
(Killen and Corris 2000). Ambulatory oxygen therapy was 
recommended for those that desaturated on exercise but its 
continuous use was not as clear cut. Again, the impact of 
oxygen needed to be assessed on an individual basis (Eaton 
et al 2002). Even those who appeared to derive short-term 
beneﬁ  t may not realize sustained beneﬁ  t in the long-term 
and/or may not wish to continue therapy (Eaton et al 2002). 
Oxygen therapy is not without burden; people may have 
a sense of being tied to a machine, develop anxiety about 
power supply, and limit excursions outside the house.
Despite a lack of convincing evidence for benefit, 
palliative oxygen for the management of breathlessness 
is commonly prescribed. In a recently reported email 
survey of all 648 registered palliative care specialists 
and respiratory physicians in Australia and New Zealand 
(Abernethy et al 2005), 58% of the 214 respondents (69% 
of palliative medicine clinicians and 48% of respiratory 
physicians surveyed) reported a belief that palliative oxygen 
is beneficial and 65% of respondents cited intractable 
dyspnea as the most common reason for prescription. 
Canadian clinicians reported similar convictions (Stringer 
et al 2004), with over 40% of patients receiving LTOT 
not meeting current guidelines (Guyatt et al 2000). There 
is clearly a need for a deﬁ  nitive randomized trial. We are 
members of an international collaborative investigating 
the role of palliative oxygen vs medical air for the relief 
of breathlessness in patients with intractable dyspnea and 
PaO2 ≥55 mmHg in a deﬁ  nitive, multi-center, randomized, 
double-blind controlled trial.
Until these data become available, current evidence 
suggests that it is reasonable to prescribe this therapy 
on a case by case basis. Our current clinical standard for 
those patients who do not enroll in the trial and do not 
meet criteria for LTOT is to ﬁ  rst establish the goals of 
therapy in terms of relief of dyspnea, improvement in 
function, and improvement in QOL. Whenever possible 
we conduct a blinded “n of 1” trial with oxygen vs air at 
2 L/min. A respiratory therapist or nurse administers the 
gas, randomly choosing oxygen or air without revealing the 
assignment to the clinician or patient. For practical reasons 
the gas is administered for 15 minutes only. The patient 
undergoes a 5-minute wash-out period and then the other 
gas is administered. If access to medical air is not available, 
the test can be conducted using a fan as the comparison, 
although it will not be blinded. Dyspnea is scored on a 
VAS or numerical rating scale (NRS). If function is a major 
concern, we conduct a baseline exertional test consistent 
with the patient’s best functional status (ie, shuttle 
test [Booth and Adams 2001], walking 3 m, reading a 
paragraph). The same functional test is repeated after 
10 minutes on each gas. Unblinded results are reported to 
the clinician and patient. If the patient has superior results 
on oxygen, a prescription for palliative oxygen is written 
after a careful discussion about the funding for oxygen in the 
relevant health system. If air is superior, a fan is prescribed. 
If both are equally helpful, then the patient is given the option International Journal of COPD 2006:1(3) 294
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to use whichever he/she prefers. If oxygen is prescribed, 
the patient is then asked to evaluate QOL improvements 
and limitations related to the therapy over the next week to 
ascertain if the intervention should be continued.
Pharmacological interventions
There has been a great deal of interest in treating refractory 
dyspnea with non-speciﬁ  c drug therapies aimed at altering the 
perception of dyspnea (Burdon et al 1994). Investigators have 
looked at oral, parenteral, and inhaled opioids, psychotropic 
drugs, inhaled furosemide, and Heliox. A list of references 
for each of these interventions is provided at the end of this 
article.
Oral and parenteral opioids
The use of opioids in the treatment of refractory 
breathlessness has been the subject of investigation 
for many years and remains controversial. Most of this 
revolves around safety concerns (predominantly respiratory 
depression) amidst the perception of inadequate evidence 
for the efﬁ  cacy of opioids in relieving breathlessness in 
COPD (Pauwels et al 2001; Currow et al 2003) 
The mechanism of action of opioids is poorly understood 
and these agents may act centrally, peripherally, or by 
reducing anxiety (Leach 2005). It is well known that opioids 
reduce ventilatory response to carbon dioxide (Eckenhoff 
and Oech 1960), hypoxia (Weil et al 1975; Santiago et al 
1977), inspiratory ﬂ  ow-resistive loading (Kryger et al 
1976), and exercise (Santiago et al 1979). Additionally, it is 
known that morphine decreases oxygen consumption both at 
rest and with exercise in healthy individuals (Santiago et al 
1979). These observations led to the evaluation of oral 
opioids in individuals with breathlessness due to chronic 
airway obstruction. Most of the initial studies conducted 
prior to 1998 only included normocapneic individuals 
because of concern over respiratory depression. The 
studies were small (7–19 patients), used several different 
opioids (including dihydrocodeine, codeine, diamorphine, 
morphine, and sustained-release morphine) in a variety of 
doses, and produced conﬂ  icting results. Additionally, most 
of the studies were primarily interested in exercise tolerance 
as opposed to relief of the sensation of breathlessness and 
only one study by Poole et al (1998) assessed QOL as 
measured by the Chronic Respiratory Disease Questionnaire 
(CRQ).
Two early studies with dihydrocodeine demonstrated 
decreased breathlessness with exercise as measured by 
VAS as well as increased exercise tolerance as measured by 
treadmill or pedometer in the absence of signiﬁ  cant adverse 
effects (Woodcock et al 1981c; Johnson et al 1983). However, 
these early reports were followed by two negative studies that 
demonstrated signiﬁ  cant adverse effects and raised the issue 
of safety (Rice et al 1987; Eiser et al 1991).
Jennings et al (2002) systematically reviewed all 
data on the use of opioids through 2001 in an attempt to 
evaluate the evidence as a whole. In their assessment of 
oral and parenteral opioids, they included eight studies that 
evaluated oral morphine, as well as one study that evaluated 
subcutaneous morphine. Seven of the nine studies were of 
patients with COPD. Meta-analysis demonstrated a highly 
statistically signiﬁ  cant effect of oral and parenteral opioids 
on the sensation of breathlessness (overall pooled effect 
size –0.31, 95% conﬁ  dence internval [CI] –0.50 to –0.13, 
p=0.0008). Exercise tolerance was a secondary outcome. 
Meta-analysis demonstrated a trend towards an improved 
effect on exercise tolerance, but the CI crossed zero (–0.20, 
95% CI –0.42 to +0.03, p not stated). The Poole et al (1998) 
study found no difference in QOL between treatment and 
placebo. Jennings et al (2002) concluded that there was a 
deﬁ  nite and highly statistically signiﬁ  cant effect of oral or 
parenteral opioids on the sensation of breathlessness but 
that the clinical effect was relatively small (approximately 
8 mm on a 100 mm VAS with baseline levels of dyspnea 
of 50 mm). They gave several reasons for this small effect, 
including that the opioid doses were often small, doses were 
not titrated, dosing intervals were long, and single dose 
studies would not have achieved steady state. Additionally, 
their evaluation of the data did not suggest that the use of 
opioids was associated with changes in arterial blood gas 
measurements or oxygen saturation.
Following the Jennings et al (2002) systematic review, 
Abernethy et al (2003) published results of a trial using oral 
morphine in opioid-naïve adults with refractory dyspnea. 
Forty-eight outpatients with refractory dyspnea despite 
optimal management were enrolled in an adequately 
powered 8-day randomized, double-blind, crossover study 
in which they received either 20 mg oral morphine sulfate 
or placebo. The morphine product used was a 24-hour 
sustained-release preparation. The primary outcome was the 
sensation of breathlessness measured on a 100 mm VAS; 
exercise tolerance was not measured. While participants 
were not restricted to those with COPD, 88% had COPD 
as the predominant cause of dyspnea. Participants were 
elderly (mean age 76, standard deviation [SD] 5) and 71% 
were on oxygen. The mean baseline morning dyspnea 
score was 43 (SD 26). In an intention to treat analysis, International Journal of COPD 2006:1(3) 295
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there was a signiﬁ  cant decrease in dyspnea with morphine, 
with mean improvements in dyspnea intensity of 6.6 mm 
in the morning (p=0.011) and 9.5 mm in the evening 
(p=0.006). Relative improvement over baseline dyspnea 
was 15%–22%. These results were similar to the estimate 
of efficacy for oral and parenteral opioids generated 
by Jennings et al (2002). Morphine did not depress the 
respiratory rate (RR; mean RR for morphine vs placebo = 20 
[SD 5] vs 21 [SD 4], p=0.143) and no episodes of severe 
sedation or obtundation were recorded. The main side-effect 
was constipation (9 vs 1, p=0.021), but neither treatment 
caused more vomiting, confusion, sedation, or appetite 
suppression. Those who received morphine also described 
better sleep at night (p=0.039) despite the fact that the 
medication was administered each morning. We concluded 
that oral sustained-release morphine could provide relief 
to patients with refractory breathlessness, even for patients 
who were elderly, had COPD, and were not previously 
receiving background opioids. We do caution, however, 
that this was not a safety study and was not powered to 
detect infrequent signiﬁ  cant side-effects, so these agents 
should be used with care.
Current data do not clarify the ideal dose of morphine, the 
additive effect of opioids, whether all opioids provide equal 
effect, or whether the effect would be as substantial in diseases 
other than COPD. We used a 20-mg dose of morphine as that 
was the lowest dose once daily sustained-release product 
available to us at the time of study design. A dose ranging 
study exploring 10–30 mg sustained-release morphine is 
ongoing. This study will report on long-term effectiveness 
and will also clarify whether there is an additional beneﬁ  t to 
increasing the dose sequentially. A study to evaluate additive 
effect of additional medication in opioid-tolerant patients is 
also planned. In the Jennings et al (2002) meta-analysis, all 
of the studies of oral and parenteral opioids had an effect size 
in favor of opioids except the two studies of diamorphine. 
This suggests that opioids have a beneﬁ  cial effect but that all 
opioids are not the same. A study of morphine vs oxycodone 
is also planned. Once adequate data are available, sub-group 
analyses considering COPD vs other causes of dyspnea will 
be conducted.
In practise, we prescribe oral morphine for COPD 
patients with refractory dyspnea. When the patient is opioid-
naïve, we start with a 20-mg, once-daily, sustained-release 
morphine preparation if the drug is available and the patient 
does not have a contraindication to morphine. When not 
available, we start with the 15-mg, twice-daily, long-acting 
morphine product, initially prescribing it once a day and 
increasing to twice daily after 5–7 days if the patient tolerates 
the medication and has residual breathlessness. When the 
patient has a contraindication to morphine, we choose long-
acting oxycodone starting at 10 mg once a day and increase 
to twice a day after 5–7 days as tolerated and needed. We 
have also used hydromorphone dosed around the clock in 
analgesic doses equal to 20–30 mg of morphine. We avoid 
starting with the 25-μg fentanyl transdermal patch as this 
provides over 80 morphine equivalents per day. If an opioid-
tolerant patient is already on a regular dose of morphine or 
another opioid, we sequentially increase the opioid by 20% 
of the total daily dose every 3–5 days until the breathlessness 
is relieved or side-effects occur (Bruera et al 1993).
Nebulized opioids
The role of nebulized opioids in the management of 
refractory dyspnea has also been studied. The mechanism 
by which these agents may act is currently unclear but it 
has been proposed that there may be a direct local effect 
on peripheral neural receptors in small airways. Much like 
the data with oral opioids, the studies are small and the 
results inconsistent. However, on the whole, the majority 
of studies failed to demonstrate a beneﬁ  t, as reported by 
Jennings et al (2002) in their meta-analysis. At this point, 
we do not feel that there is adequate evidence to support 
the use of nebulized opioids in the treatment of refractory 
breathlessness. Since the size of nebulized droplets is crucial 
for the activity of inhaled opioids, in the future, newer 
methods of microdroplet delivery of opioids may result in 
rapid systemic effects and improved efﬁ  cacy of this method 
of drug delivery.
Psychotropic drugs
Use of psychotropic agents including anxiolytics, 
phenothiazines, and selective serotonin reuptake inhibitors 
(SSRIs) for the treatment of refractory dyspnea has received 
some attention based on the observation that there is often 
a large psychological component to dyspnea and that 
anxiety signiﬁ  cantly contributes to functional impairment 
in COPD (Kim et al 2000). Diazepam was initially reported 
to be beneficial by Mitchell-Heggs et al (1980) when 
they published the results of an exploratory study in four 
patients. However, these results could not be replicated in 
two subsequent studies (Woodcock et al 1981a; Sen et al 
1983) which also raised the issue of safety. Several other 
investigators chose to re-look at the use of benzodiazepines 
but with alprazolam, a shorter-acting and potentially less-
sedating medication. In one controlled study (Man et al International Journal of COPD 2006:1(3) 296
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1986), the investigators found no improvement in breathless-
ness. However, a beneﬁ  t was found in a subsequent single 
case report (Greene et al 1989).
Anxiolytics
Buspirone, a serotonergic anxiolytic agent, has been shown 
to be a respiratory stimulant in animals (Garner et al 1989; 
Mendelson et al 1990). Two small studies (Argyropoulou 
et al 1993; Singh et al 1993) evaluated the effects of bus-
pirone on breathlessness, exercise tolerance, and anxiety in 
patients with severe COPD. These studies included slightly 
different patient populations in that Singh et al (1993) re-
quired baseline anxiety as measured by the Speilberger State-
Trait Anxiety Inventory Scale (STAI) for study enrollment 
and Argyropoulou et al (1993) did not require any baseline 
anxiety assessment. The results of the studies conﬂ  icted with 
those of the Argyropoulou et al (1993) study documenting 
improvement in all three domains and the other study ﬁ  nd-
ing no difference.
Taken together, these data, while inconsistent, suggest 
that there may be a role for anxiolytic agents in selected pa-
tients with refractory dyspnea. Further studies are needed. In 
practise, we perform “n of 1” trials for patients where we plan 
to use these agents, carefully monitoring for beneﬁ  t in terms 
of relief of the sensation of breathlessness and improvement 
in function without overwhelming adverse effects. When 
we do not have identical appearing placebos available, we 
conduct single-sided “n of 1” trials carefully documenting 
outcomes to be reviewed by both clinician and patient.
Phenothiazines
There are also limited, conﬂ  icting data on the use of pheno-
thiazines. One early study comparing diazepam and promet-
hazine reported increased exercise tolerance and decreased 
breathlessness with promethazine (Woodcock et al 1981a) 
but these results were not supported by a subsequent study 
(Rice et al 1987). Additionally, the Rice et al (1987) study 
raised concerns about side-effects, including increases in 
PaCO2 and drowsiness. Light et al (1996) evaluated both 
promethazine and prochlorperazine in combination with 
morphine in a double-blind, placebo-controlled study that 
included seven male patients with severe COPD (mean 
FEV1 0.99 L [SD 0.30]). The authors found that treatment 
with morphine and promethazine in combination increased 
exercise tolerance compared with placebo (mean increase 
in workload of 10 W [SD 6.3] vs 1.4 W [SD 6.9], p<0.05). 
Morphine and prochlorperazine had an intermediate ef-
fect (mean increase in workload of 6.4 W [SD 6.3]; p not 
reported). The cognitive effects of both combinations were 
also assessed. Morphine and prochlorperazine had a large 
negative effect on patients’ mental status while morphine 
and promethazine produced effects no different from placebo 
or morphine alone. The authors suggested that the increased 
exercise tolerance seen with the combination of morphine and 
promethazine was due to a decreased level of dyspnea at a 
given workload despite the fact that there was no signiﬁ  cant 
difference in Borg scores. Available data, therefore, do not 
support the routine use of phenothiazines in the management 
of refractory dyspnea, referring to the beneﬁ  cial effect of 
morphine instead.
SSRIs
In recent years, there has been interest in the use of SSRIs 
in the treatment of patients with COPD and breathlessness. 
A pilot study by Papp et al (1995) reported that six patients 
(three of whom had psychiatric disorders) felt better after 6 
weeks of sertraline, suggesting that further study was war-
ranted. Smoller et al (1998) reported a case series of seven 
patients with obstructive lung disease treated with sertraline 
by their pulmonologists. All patients were evaluated by a 
psychiatrist, one in a prospective fashion using the Structured 
Clinical Interview for the DSM-III-R and the other six ret-
rospectively with modules for depression, dysthymia, panic, 
agoraphobia, and generalized anxiety disorder (GAD). Four 
of the seven patients did not meet criteria for a psychiatric 
diagnosis although several experienced panic and/or anxiety 
during episodes of dyspnea. Of the remaining three patients, 
one met criteria for panic disorder with agoraphobia, one for 
both dysthymia and GAD, and one for major depression. All 
patients reported a “decrease” in breathlessness and several 
also reported “improvements” in exercise tolerance. There 
were, however, no formal measures performed. It is not clear 
whether SSRIs improve dyspnea and exercise tolerance by 
relieving anxiety symptoms or by direct effects on respira-
tion. Many patients with dyspnea out of proportion to their 
pulmonary compromise experience depression and/or anxiety 
and there are data to suggest that treatment of these symptoms 
relieves dyspnea (Burns and Howell 1969). However, there 
are also animal data suggesting that serotonin acts at the 
level of the brainstem respiratory center and it may be this 
action that affects the sensation of dyspnea (Mueller et al 
1982). There have been no subsequent studies of SSRIs and 
currently there is no substantive evidence on which to recom-
mend their use in COPD patients with refractory dyspnea in 
the absence of an underlying psychiatric indication. This is 
an important area for further study. In patients where there is International Journal of COPD 2006:1(3) 297
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concern for an underlying psychiatric disorder (eg, anxiety, 
depression), there should be a concerted effort to conﬁ  rm the 
diagnosis and initiate effective therapy.
Emerging data
Inhaled furosemide
There are two additional interventions currently under in-
vestigation. Inhaled furosemide has been studied in healthy 
subjects (Nishino et al 2000) and in patients with COPD 
(Ong et al 2004). The rationale behind the use of furosemide 
includes its inhibitory effect on the cough response induced 
by low chloride content solutions (Ventresca et al 1990) and 
a preventive effect of furosemide on bronchoconstriction 
in asthma (Bianco et al 1988, 1989; Robuschi et al 1989). 
Inhaled furosemide may also act indirectly on vagally medi-
ated sensory nerve ending in airway epithelium (Chung and 
Barnes 1992). In healthy subjects, inhaled furosemide has 
prolonged breathholding time and the period of no respiratory 
sensation and has also slowed the development of discomfort 
during loaded breathing (Nishino et al 2000). Does inhaled 
furosemide have a role in the palliation of refractory dyspnea? 
A randomized study evaluated the effects of inhaled furosem-
ide vs placebo in exercise-induced dyspnea (as assessed by 
VAS) in 19 patients with moderate to severe COPD (FEV1 
<70%) and moderate-to-severe chronic breathlessness (Ong 
et al 2004). Mean dyspnea VAS scores after exercise were 
lower after
 inhalation of furosemide (34mm [SD 25] vs 42 
[SD 24], p=0.014). Exercise-related FEV1 and FVC also 
improved after furosemide inhalation (p=0.038 and 0.005, 
respectively) but not after placebo. Interestingly, no increase 
in exercise endurance time was noted. Both this study and the 
study by Nishino et al (2000) suggest that inhaled furosem-
ide deserves further investigation in the relief of refractory 
breathlessness.
Heliox28 
A second agent that may have a role in the therapy of 
refractory breathlessness is Heliox28, a helium–oxygen 
mixture containing 72% helium and 28% oxygen. A Phase 
II crossover study assessed the palliative role of Heliox28 in 
12 lung cancer patients with refractory dyspnea (Ahmedzai 
et al 2004). Breathlessness during 6-minute walk test was 
evaluated while patients were breathing Heliox28, 28% 
oxygen, or medical air. The VAS measurements were sig-
niﬁ  cantly lower when comparing Heliox28 with medical 
air (40.2% [SD 4.8] vs 59.3% [SD 5.3], p<0.05) but there 
was no signiﬁ  cant difference between Heliox28 and oxygen 
(47.0% [SD 5.6]) or between oxygen and medical air. There 
were also no signiﬁ  cant differences in Borg scores. Patients 
walked farther breathing Heliox28 than breathing oxygen 
(214.2 m [SD 9.6] vs 174.6 m [SD 11.2], p<0.05) or medical 
air (128.8 m [SD 10.3], p<0.0001). The use of Heliox28 in 
the management of COPD has been explored (Grape et al 
1960; Ishikawa and Segal 1973; Jaber et al 2000) but there 
are no studies evaluating its use in patients with COPD and 
refractory dyspnea. The results obtained by Ahmedzai et al 
(2004) suggest that further investigation of Heliox28 in the 
therapy of COPD patients with refractory dyspnea may be 
warranted. Issues of cost and feasibility would need to be 
considered in any such investigation.
Non-pharmacological interventions
Pulmonary rehabilitation
In 1994, “pulmonary rehabilitation” was deﬁ  ned by the 
National Institutes of Health Workshop on Pulmonary 
Rehabilitation Research as “a multidimensional continuum 
of services directed to persons with pulmonary disease 
and their families, usually by an interdisciplinary team of 
specialists, with the goal of achieving and maintaining the 
individual’s maximum level of independence and function-
ing in the community” (Fishman 1994 p 826). It is a well-
established component of the care of COPD patients that 
is included in the recommendations of most COPD care 
guidelines, and there have been numerous studies demon-
strating its value in reducing dyspnea, improving QOL, and 
increasing independence–exercise capacity (Lacasse et al 
1996; Guell et al 2000). There is also an evidence-based guide-
line examining its scientiﬁ  c basis (ACCP/AACVPR 1997). 
Pulmonary rehabilitation is typically introduced early in the 
illness trajectory so, while it certainly has a role in the care of 
patients with advanced COPD, a detailed exploration of the 
data supporting its use is beyond the scope of this review. 
Nutrition
Malnutrition is not uncommon in patients with COPD and 
weight loss can become particularly severe as the disease 
advances. Consequences of this loss include weakness of in-
spiratory and expiratory muscles which can lead to impaired 
lung function (Wilson et al 1986). Studies have demonstrated 
a link between malnutrition and impaired pulmonary status 
(Sahebjami et al 1993) as well as with increased mortality 
(Wilson et al 1989). It therefore stands to reason that nu-
tritional support would constitute a simple, effective inter-
vention in the management of patients with severe COPD. 
The data, however, do not support this idea.International Journal of COPD 2006:1(3) 298
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Ferreira et al (2005) performed a meta-analysis of eleven 
randomized, controlled trials looking at the effects of nutri-
tional supplementation in patients with severe COPD. All 
studies evaluated the use of liquid oral supplements, includ-
ing Pulmocare
® (Ross Laboratories, Columbus, OH, USA), 
Build-up
® (Nestle, Croydon, Surrey, UK), Sustacal
® (Mead 
Johnson Nutritionals, Bristol Myers Squibb, New York, NY, 
USA), Isocal
® (Mead Johnson Nutritionals, Bristol Myers 
Squibb, NY, NY, USA), and Respifor
® (Nutricia, Zoetermeer, 
Netherlands). Ferreira et al (2005) identiﬁ  ed no signiﬁ  cant 
effect on any outcome variable, including anthropomorphic 
measures, pulmonary function, respiratory muscle strength, 
functional exercise capacity, and health-related QOL. Be-
cause only 3 (Efthimiou et al 1988;Otte et al 1989;Steiner 
et al 2003) of the 11 studies evaluated QOL or dyspnea, it 
is difﬁ  cult to draw conclusions regarding the effect of nutri-
tion on outcomes most important to patients with end-stage 
COPD who require palliation. A well-designed clinical trial 
of nutritional supplementation in end-stage COPD patients 
with dyspnea and reduced QOL would be useful to assess 
the effects of this simple intervention.
Psychosocial support
Providing support is a fundamental part of caring for any 
patient with chronic illness, but it becomes more important 
as patients begin to decline and experience more functional 
limitations. Patients often need help coping with their ill-
ness and the changes occurring in their lives. At the same 
time, relatives and family members may require support as 
relationships and family roles change as a result of disease 
progression and increasing symptom burden (Leach 2005).
There are several qualitative studies that highlight the 
speciﬁ  c need for support of those caring for individuals with 
breathlessness. Booth et al (2003) sought to investigate the 
experience of living with breathlessness both in patients with 
cancer or COPD and in those individuals providing informal 
care. The investigators interviewed 10 COPD patients and 
their caregivers in their homes; 30% of interviews were con-
ducted separately. Six of the patients were male; they were 
all Caucasian and ranged in age from 51 to 80 years (mean 
= 70 years). The study found that many caregivers found 
taking care of a breathless person to be “pre-occupying, 
restricting, and a major cause of anxiety” (Booth et al 2003 
p 341). Anxiety was noted to be particularly bad a night and 
several caregivers described spending time listening to their 
spouse breathing. The investigators concluded that clinicians 
must not forget about the needs of their patients’ families 
and that patients with disabling symptoms are often best 
cared for using a multidisciplinary approach. A similar study 
described the experiences of 10 patients with COPD and 
their caregivers (Seamark et al 2004). The caregivers were 
married to the patient in seven of the 10 cases and ranged 
in age from 60 to 93 years (mean 72 years). They expressed 
losses similar to those of the patients and felt burdened by 
the multiple roles that they were forced to fulﬁ  ll. There was 
also a sense that it was not fair that the illness affected both 
patient and caregiver and this often contributed to tension 
in the relationships. 
There are no speciﬁ  c guidelines available regarding spe-
ciﬁ  c support for either patients or their informal caregivers. 
Clinicians caring for these patients must be conscious of the 
potential need for increased support as well as responsive 
to patient–family concerns when they arise. To date there 
have been no reports of systematic evaluation of isolated 
behavioral or psychosocial interventions for COPD patients 
with intractable dyspnea. This is an important area for future 
study.
Breathing techniques
Several controlled breathing techniques including positioning 
and pursed lip breathing (PLB) are useful in the manage-
ment of breathlessness. The most commonly used position is 
one in which the patient leans forward and supports his/her 
weight with the arms–upper body. This serves to increase 
abdominal pressure and may improve respiratory muscle 
function (ATS 1999). Use of the leaning forward position 
has also been reported to improve inspiratory muscle strength 
(O’Neill and McCarthy 1983) and diaphragmatic function 
(Sharp et al 1980), reduce the use of accessory muscles, 
and decrease abdominal breathing (Barach and Beck 1954; 
Barach 1974; Sharp et al 1980). PLB involves inhalation 
through the nose followed by a slow exhalation, usually 
4–6 seconds, through pursed lips. It has been shown to de-
crease air trapping by stenting the airways and preventing 
dynamic airway collapse (Tiep et al 1986) and often helps 
to avert panic attacks that accompany severe breathlessness 
(Madge and Edmond 2001). Unfortunately, despite studies 
demonstrating the beneﬁ  t of these techniques in relieving 
dyspnea, the results in practice are variable (ATS 1999). In 
practise, instruction in positioning and PLB is provided to all 
of our patients with dyspnea, and the skills reviewed during 
subsequent clinic visits.
Breathlessness clinics
“Breathlessness clinics” are another potential intervention 
for dyspneic patients with advanced COPD. Nurse prac-International Journal of COPD 2006:1(3) 299
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titioners who run these clinics lead weekly sessions that 
focus on counseling, breathing re-training, relaxation, and 
coping–adaptation strategies for dealing with breathlessness. 
The “breathlessness clinic” model combines education and 
psychosocial support, and has thus far focused on patients 
with lung cancer.
The initial pilot study demonstrating beneﬁ  t of these clin-
ics was published in 1996 (Corner et al 1996). It involved 
34 lung cancer patients with breathlessness randomized to 
the nursing intervention or control. The intervention group 
attended weekly 1-hour sessions for 3–6 weeks. During these 
sessions, the nurse practitioner assessed patients’ breathless-
ness, disease, and feelings. He/she gave advice and support 
about managing breathlessness, including activity pacing, 
as well as education on breathing and relaxation techniques. 
The control group was encouraged to talk about their disease 
but received no counseling or breathing training. Outcomes 
were assessed at baseline, one month and three months by 
three separate VAS scales, the Functional Capacity Scale, and 
the HADS. The study stopped recruiting at 34 patients at the 
request of the clinic staff who noted beneﬁ  t in the interven-
tion group. Despite the small number of participants and the 
loss of 14 patients, leaving only 20 patients for analysis, 3 
months after study entry the intervention group saw signiﬁ  -
cant improvements in worst breathlessness (p=0.02), distress 
caused by breathlessness (p=0.02), and functional capacity 
(p=0.03). Symptoms in the control group either remained 
static or worsened over the course of the study.
Two subsequent studies (Bredin et al 1999; Hately et al 
2003) have further validated this concept. In a multicenter 
study involving 119 patients, Bredin et al (1999) found 
similar improvements in breathlessness at best (p=0.03), 
performance status (p=0.02), depression (p=0.02), physical 
symptoms (p=0.04), and activity (ie, climbing stairs, walking 
outdoors, and going shopping, p=0.05). A smaller study by 
Hately et al (2003) of 30 breathless patients with lung cancer 
also demonstrated improvements. The authors saw a decrease 
in frequency of respiratory symptoms (p<0.001) as well as 
an improvement in functional capacity (p<0.001) and QOL 
scores, with the greatest improvement in “patients’ ability to 
do what they want” (p=0.001) and in overall QOL (0.004). 
Breathlessness scores were improved with signiﬁ  cant reduc-
tions in VAS scores for breathing at best (median reduction 
= 1, p=0.001), breathing at worst (median reduction = 3, 
p<0.001) and distress caused by breathing (median reduction 
= 4, p<0.001). Qualitative data demonstrated the value of the 
intervention on patient’s adjustment to their cancer diagnosis 
as well as their sense of well-being.
These three studies (Corner et al 1996; Bredin et al 1999; 
Hately et al 2003) suggest a role for a nursing intervention 
incorporating psychosocial support and education in the care 
of breathless patients with lung cancer. There no studies 
evaluating such an intervention in patients with end-stage 
COPD, though this is a population that would likely derive 
similar beneﬁ  t. Practically, patients with lung cancer and 
COPD may be referred to a “breathlessness clinic” when 
such a specialty clinic is available. However, these types 
of tertiary referral clinics are often not the ideal setting to 
see a sick patient and his/her family on a regular basis, so 
continued follow-up by the referring physician with atten-
tion to continued symptom management is required. Future 
goals should focus on evaluating this model in other diseases 
and developing sustainable models that can be rolled out 
worldwide.
Conclusions and future directions
COPD is a common disease with a course that deteriorates 
in a relentless fashion until culminating in severe functional 
limitation and symptom burden. Intractable or refractory 
dyspnea is a substantial contributor to this suffering. As in-
dividuals continue to live longer, the number of “end-stage” 
COPD patients will increase. Their needs are similar to those 
of lung cancer patients but COPD patients are offered and 
use fewer palliative interventions. The reason for this is not 
clear but it may be due, at least in part, to a differential focus 
of the individuals caring for these two groups of patients. 
Palliative interventions for patients with advanced COPD 
have the potential to reduce the suffering caused by breath-
lessness. The goal of palliative interventions in “end-stage” 
disease is to decrease symptoms, and improve functional 
status and QOL.
In this paper we have outlined the interventions currently 
available for the global treatment of refractory dyspnea. Oral 
or parenteral opioids are beneﬁ  cial with the most evidence 
available for morphine. Palliative oxygen may be beneﬁ  cial 
for some patients; an “n of 1” trial is the best approach until 
further information is available. Anxiolytics and SSRIs have 
limited and sometimes conﬂ  icting data; they should be ap-
proached cautiously and with explicit expected outcomes 
until more information is available. Inhaled furosemide is 
an interesting potential intervention that needs more study. 
Heliox28 may or may not be beneﬁ  cial but its use may be 
most limited by feasibility concerns. Nutrition needs further 
study, as does counseling, behavioral therapies, and breath-
lessness clinics for COPD. Instruction in positioning and PLB 
is a simple intervention with potential to be very effective International Journal of COPD 2006:1(3) 300
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but without prior systematic study. Maintaining physical 
activity, whether via a structured pulmonary rehabilitation 
program or via another intervention, remains an important 
intervention, albeit one that is less well studied in individuals 
with refractory breathlessness. 
It is clear that there is more work to be done as many of the 
options have little or limited evidence to support their use. We 
have tried to identify areas that are currently under investiga-
tion as well as those that require further exploration. We are 
currently involved in a multi-center, randomized clinical trial 
investigating the role of palliative oxygen vs medical air in 
non-hypoxemic patients with intractable dyspnea. Addition-
ally, there is an ongoing study evaluating varying doses of 
sustained-release morphine. A study of newer psychotropic 
agents is planned. Finally, non-pharmacologic interventions 
such as breathlessness clinics have proven beneﬁ  t in lung 
cancer patients but need speciﬁ  c evaluation in COPD.
All of this translates to the needs for better palliative care 
for patients with advanced COPD and for the difﬁ  cult prob-
lems that create suffering like refractory dyspnea. Whether 
this care is best provided by the patient’s long-standing pri-
mary care provider or pulmonologist with or without special-
ist palliative care support or by primary palliative care teams 
who take over care remains to be seen. Hospices, inpatient 
palliative care units, and symptom management consults are 
also important supports for the care of the COPD patient with 
unrelenting dyspnea.
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Selected reference list
Studies included in Booth et al (2004) 
systematic review
Use of oxygen at rest: (Liss and Grant 1988; Swinburn et al 
1991; Booth et al 1996; O’Donnell et al 2001)
Use of oxygen before, during and after exercise (ie “short 
burst” oxygen therapy): (Woodcock et al 1981b; Waterhouse 
and Howard 1983; Swinburn et al 1984; Evans et al 1986; 
Lane et al 1987; Davidson et al 1988; McKeon et al 1988a, 
1988b; Kollef and Johnson 1990; Dean et al 1992; Leach et al 
1992; Dewan and Bell 1994; Roberts et al 1996; O’Donnell 
et al 1997; Marques-Magallanes et al 1998; Killen and Corris 
2000; Knebel et al 2000; Revill et al 2000; Jolly et al 2001; 
Maltais et al 2001; O’Donnell et al 2001; Somfay et al 2001; 
Eaton et al 2002)
Use of LTOT where breathlessness was an outcome in ad-
dition to survival: (McDonald et al 1995; Rooyackers et al 
1997; Garrod et al 2000; Eaton et al 2002)
Studies on pharmacologic interventions
Opiods – oral: (Woodcock et al 1981c; Johnson et al 1983; 
Rice et al 1987; Light et al 1989, 1996; Eiser et al 1991; Poole 
et al 1998; Jennings et al 2002; Abernethy et al 2003)
Opioids – parenteral: (Bruera et al 1993)
Opiods – inhaled: (Young et al 1989; Beauford et al 1993; 
Farncombe et al 1994; Harris-Eze et al 1995; Masood et al 
1995; Leung et al 1996; Jankelson et al 1997; Noseda et al 
1997; Jennings et al 2002; Foral et al 2004)
Psychotropic agents – anxiolytics: (Mitchell-Heggs et al 
1980; Woodcock et al 1981a; Sen et al 1983; Eimer et al 
1985; Man et al 1986; Greene et al 1989; Argyropoulou et al 
1993; Singh et al 1993)
Psychotropic agents – phenothiazines: (Woodcock et al 
1981a; O’Neill et al 1985)
Psychotropic agents – SSRIs: (Papp et al 1995; Smoller 
et al 1998) 
Inhaled furosemide: (Nishino et al 2000; Ong et al 2004)
Heliox28: (Ahmedzai et al 2004).
Studies included in Jennings et al (2002) 
systematic review 
Studies evaluating oral morphine: (Woodcock et al 1981c, 
1982; Johnson et al 1983; Eiser et al 1991; Light et al 1996; 
Chua et al 1997; Poole et al 1998)
Study evaluating subcutaneous morphine: (Bruera et al 
1993).
Studies evaluating inhaled morphine: (Young et al 1989; International Journal of COPD 2006:1(3) 301
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Beauford et al 1993; Davis et al 1994, 1996; Harris-Eze et al 
1995; Masood et al 1995; Leung et al 1996; Jankelson et al 
1997; Noseda et al 1997)
Studies included in Ferreira et al (2005) 
meta-analysis
(Lewis et al 1987; Efthimiou et al 1988; Knowles et al 1988; 
Otte et al 1989; Fuenzalida et al 1990; Whittaker et al 1990; 
DeLetter 1991; Schols et al 1995; Steiner et al 2002a, 2002b, 
2003; Goris et al 2003)
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